clinical trials

News

GSK reveals the survival data that it reckons could return BCMA drug Blenrep to the forefront of multiple myeloma treatment.

News

Liver safety signal leads BioAge to discontinue its phase 2 trial of obesity candidate azelaprag, hitting the Nasdaq debutante's share price.

News

Regeneron's Alnylam-partnered poze-cemdi combination achieves greater disease control measured using LDH than AZ's market-leading Ultomiris.

News

The results of a phase 2 trial of MSD’s anti-ROR1 ADC zilovertamab vedotin back up the company's decision to start a phase 3 trial in DLBCL.

News

Eli Lilly is playing catch-up to Novo Nordisk in the fast-growing obesity therapy sector but has new data that could tip the balance in its favour.

News

Abingworth is reported to be raising $1.5bn for further risk-sharing, royalty-bearing development deals with large pharma groups.